JCR Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, JCR Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of ¥627. The average 1-year stock price forecast is 37.43% higher than the current stock price, while the lowest is ¥430 (-5.70%) and the highest is ¥900 (+97.37%).

Price Target: ¥627 (+37.43%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	¥430	¥627	¥615	¥900
Change	-5.70%	+37.43%	+34.87%	+97.37%

Analyst Ratings

The average analyst rating for JCR Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	0	0	0	1	1	1
Buy	0	0	0	0	0	0
Hold	5	6	6	5	5	5
Sell	0	0	0	0	0	0
Strong Sell	1	0	0	0	0	0
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Morgan Stanley No rating	Morgan Stanley	Hold Maintains ¥500	Hold	Maintains	¥500	+9.65%	Jun 9, 2026
Unknown Analyst Nomura No rating	Nomura	Hold Maintains ¥430	Hold	Maintains	¥430	-5.70%	Jun 5, 2026
Unknown Analyst SBI Securities No rating	SBI Securities	Hold Maintains ¥450	Hold	Maintains	¥450	-1.32%	Jun 4, 2026
Unknown Analyst Citi No rating	Citi	Hold Maintains ¥540	Hold	Maintains	¥540	+18.42%	May 25, 2026
Miyabi Yamakita Jefferies	Jefferies	Buy Upgrades ¥900	Buy	Upgrades	¥900	+97.37%	Apr 16, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

42.36B

from 40.32B

5.05%

from 40.32B

Revenue Next Year

40.41B

from 42.36B

-4.59%

from 42.36B

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	51.08B	34.34B	42.87B	33.07B	40.32B	42.36B
Revenue Growth	69.79%	-32.77%	24.83%	-22.86%	21.91%	5.05%
Gross Profit	40.62B	25.46B	31.25B	21.74B	30.19B	32.32B
Gross Margin	79.52%	74.13%	72.90%	65.73%	74.87%	76.30%
Operating Income	19.94B	4.98B	7.53B	-6.84B	431.00M	1.17B
Net Income	14.51B	3.77B	5.51B	-4.76B	2.18B	562.50M
Dividend / Share	20.00	20.00	20.00	20.00	20.00	20.00
Dividend Growth	-	-	-	-	-	-
Free Cash Flow	4.84B	-15.23B	4.18B	-13.17B	-24.62B	-8.68B
No. Analysts	-	-	-	-	-	6

Financial currency is JPY.

Revenue Forecast

Revenue	2027	2028	2029
High	46.2B
Avg	42.4B
Low	34.4B

Revenue Growth

Revenue Growth	2027	2028	2029
High	14.7%
Avg	5.1%
Low	-14.6%

EPS Forecast

EPS	2027	2028	2029
High	-
Avg	-
Low	-

EPS Growth

EPS Growth	2028	2029
High	-
Avg	-
Low	-